Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer

NCT00639327 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: S-1 + irinotecan
DRUG: irinotecan

Sponsor

Japan Clinical Cancer Research Organization

Collaborators

[object Object]